Elutia Inc. (ELUT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elutia Inc. (ELUT) has a cash flow conversion efficiency ratio of -0.897x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.81 Million) by net assets ($27.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Elutia Inc. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Elutia Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Elutia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elutia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elutia Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QT Imaging Holdings, Inc. Common Stock
NASDAQ:QTI
|
-0.481x |
|
Abocom Systems Inc
TW:2444
|
-0.115x |
|
MClean Technologies Bhd
KLSE:0167
|
0.029x |
|
Greattown Holdings Ltd B
SHG:900940
|
0.034x |
|
Gamehaus Holdings Inc. Class A Ordinary Shares
NASDAQ:GMHS
|
-0.014x |
|
Better Life Group Co Ltd
TW:1805
|
-0.011x |
|
BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877-
F:BLH
|
0.003x |
|
Buima Group
TWO:5543
|
0.145x |
Annual Cash Flow Conversion Efficiency for Elutia Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Elutia Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Elutia Inc. (ELUT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.67 Million | $-44.81 Million | -1.619x | -430.63% |
| 2024-12-31 | $-46.26 Million | $-22.66 Million | 0.490x | -13.12% |
| 2023-12-31 | $-38.60 Million | $-21.76 Million | 0.564x | -86.76% |
| 2022-12-31 | $-5.03 Million | $-21.43 Million | 4.259x | +472.79% |
| 2021-12-31 | $13.52 Million | $-15.45 Million | -1.142x | -74.64% |
| 2020-12-31 | $20.83 Million | $-13.63 Million | -0.654x | -598.95% |
| 2019-12-31 | $-55.11 Million | $-7.22 Million | 0.131x | +11.03% |
| 2018-12-31 | $-43.41 Million | $-5.12 Million | 0.118x | -- |
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDer… Read more